Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.

Oxford skyline

The Pandemic Sciences Centre, which will include a number of core institutes, will harness the strong global research collaborations that the University of Oxford has developed over more than forty years. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. The new centre will also build on the strong and unique collaborations developed in record time across national borders between academia, industry and public health bodies during the coronavirus pandemic. 

The centre will focus on three core themes:  

  • Accelerating understanding and insights: generating actionable knowledge and data (from pathogens through to patients) in near 'real-time' and making this globally accessible. 
  • Translating research into real-world solutions: creating and deploying effective, acceptable and equitable health technologies, including digital tools, diagnostics, treatments, and vaccines. 
  • Enhancing confidence, trust and impact:  identifying ways to strengthen societal and political engagement, resilience, and responsiveness.

Peter Horby, Professor of Emerging Infectious Diseases, will be inaugural Director of the centre. Peter has worked on many global health threats including SARS-1, bird flu, Middle East Respiratory Syndrome, Ebola, Lassa fever, and plague.

The COVID-19 pandemic has shown us that spectacular advances are possible through an alliance of science, the public sector and industry - creating digital disease control tools, diagnostic tests, and life-saving treatments and vaccines at unprecedented speed. But it should not take a pandemic to make this happen. This level of innovation and multi-sectoral collaboration must be applied, day in and day out, to prevent another catastrophe like COVID-19.

Professor Peter Horby

The full Press Release is available on the University of Oxford website

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

RECOVERY Trial paper on dexamethasone wins BMJ’s 2021 UK Research Paper of the Year Award

A RECOVERY Collaborative Group paper has been announced as the 2021 winner of The British Medical Journal’s prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare. The paper, “Dexamethasone in Hospitalized Patients with Covid-19”, published in the New England Journal of Medicine, described the discovery in June 2020 of the world’s first effective, readily available treatment for COVID-19 – the inexpensive steroid, dexamethasone.

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Systematic review identifies research gaps for Chagas disease

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.